Averting multiple sclerosis long-term societal and healthcare costs: the Value of Treatment (VoT) project

Tinelli, Michela ORCID: 0000-0002-8816-4389, Pugliatti, Maura, Antonovici, Andreea, Hausmann, Bettina, Hellwig, Kerstin, Quoidbach, Vinciane and Sørensen, Per Soelberg (2021) Averting multiple sclerosis long-term societal and healthcare costs: the Value of Treatment (VoT) project. Multiple Sclerosis and Related Disorders, 54. ISSN 2211-0348

	Text (Averting multiple sclerosis long-term societal and healthcare costs) - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (283kB)
	Text (VoT- MSARD final tables) - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (110kB)
	Text (VoT- MSARD final figures) - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (489kB)
	Text (VoT- MSARD final supplementary documents) - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (154kB)

• Scopus publication

Abstract

Background and purpose The recent report on Value-of-Treatment (VoT) project highlights the need for early diagnosis-intervention, integrated, seamless care underpinning timely care pathways and access to best treatments. The VoT-multiple-sclerosis (MS) economic case study analysis aimed to estimate the effectiveness/cost-effectiveness of both early treatment and reducing MS risk factors (e.g. smoking and vitamin D insufficiency). Methods A series of decision analytical modellings were developed and applied to estimate the cost-effectiveness of: (1) reducing the conversion from clinically-isolated-syndrome (CIS) to clinically-definite-MS (CDMS); (2) smoking cessation and increase of 25 hydroxyvitamin D (25(OH)D) serum level. Both (1) and (2) considered socioeconomic impact on averted MS disability progression. Costs were reported for societal and healthcare provider perspectives (pending on data across nations; Euros). Effectiveness was expressed as Quality-Adjusted-Life-Years (QALYs) gains. Long term (25, 30, 40,50-years) and short (one-year) timelines were considered for (1) and (2), respectively. Results Early treatment was cost-effective for the health care provider and both cost-effective/cost-saving for the society across time-horizons and nations. Smoking cessation and an increase of 25(OH)D in MS patients were both cost-effective/cost-saving across nations. Conclusions To the best of our knowledge, our work provides the first economic evidence to base appropriate public health interventions to reduce the MS burden in Europe.

Item Type:	Article
Official URL:	https://www.msard-journal.com/
Additional Information:	© 2021 Elsevier B.V.
Divisions:	Care Policy and Evaluation Centre
Subjects:	R Medicine > RC Internal medicine R Medicine > RA Public aspects of medicine
Date Deposited:	11 Aug 2021 10:54
Last Modified:	16 Nov 2024 04:54
URI:	http://eprints.lse.ac.uk/id/eprint/111584

Actions (login required)

View Item